Diclofenac: Clinical Overview
Diclofenac is an effective NSAID for treating pain and inflammation in osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea, but carries the highest cardiovascular risk among traditional NSAIDs and should be avoided in patients with cardiovascular disease or risk factors. 1, 2
Indications
Diclofenac is FDA-approved for 2:
- Osteoarthritis and rheumatoid arthritis (signs and symptoms)
- Acute pain (mild to moderate)
- Primary dysmenorrhea
Critical Contraindications
Absolute contraindications 2:
- Known hypersensitivity to diclofenac (including anaphylaxis, serious skin reactions)
- History of asthma, urticaria, or allergic reactions to aspirin or other NSAIDs
- Perioperative pain in CABG surgery
Cardiovascular contraindications - Diclofenac should be avoided in patients with 1:
- Established cardiovascular disease
- Congestive heart failure (NYHA class II-IV)
- Ischemic heart disease
- Peripheral arterial disease
- Cerebrovascular disease
- Cardiovascular risk factors
Cardiovascular Risk Profile
Diclofenac carries the highest cardiovascular risk among traditional NSAIDs. The evidence is striking 1:
- Vascular events: RR 1.63 (95% CI 1.12-2.37) vs placebo
- CV events/MI: RR 1.40 (95% CI 1.16-1.70)
- Recurrent MI: RR 1.54 (95% CI 1.23-1.93)
- Mortality: RR 2.40 (95% CI 2.09-2.80) - the highest mortality risk among NSAIDs
For comparison, naproxen shows neutral cardiovascular effects (RR 0.92-0.97), while ibuprofen shows intermediate risk (RR 1.07-1.51). This makes diclofenac's cardiovascular profile comparable to selective COX-2 inhibitors 1.
Recommended Dosing
Use the lowest effective dose for the shortest duration 2:
Diclofenac Potassium (immediate-release):
- Acute pain/dysmenorrhea: 50 mg three times daily (maximum 150 mg/day)
- OTC formulation: Initial dose 25 mg (2 × 12.5 mg tablets), then 12.5-25 mg every 4-6 hours, maximum 75 mg/day for ≤5 days 3
- Osteoarthritis: 100-150 mg/day in divided doses
- Rheumatoid arthritis: 150-200 mg/day in divided doses 4
Diclofenac Sodium (enteric-coated):
- Available as 25 mg, 50 mg, 75 mg tablets
- Note: Diclofenac sodium has limited efficacy in acute pain and should probably not be used for this indication 5
Key distinction: Diclofenac potassium is immediate-release with peak plasma concentration at 30 minutes, making it superior for acute pain. Diclofenac sodium is enteric-coated with delayed absorption and lesser efficacy 3, 5.
Gastrointestinal Risk
NSAIDs cause serious GI adverse events (bleeding, ulceration, perforation) that can be fatal 1, 2. However:
- Major upper GI events with diclofenac are lower than naproxen and ibuprofen, comparable to celecoxib, and higher than etoricoxib 6
- Elderly patients are at greater risk 1
- Events can occur without warning symptoms at any time during use
Important caveat: Routine prophylaxis for GI injury is not appropriate in osteoarthritis patients 7. Reserve gastroprotection for high-risk patients (elderly, history of ulcers, concurrent anticoagulation).
Alternative Considerations
For osteoarthritis pain, initial treatment should be paracetamol (acetaminophen), followed by ibuprofen 7. This stepwise approach is most cost-effective and minimizes cardiovascular risk.
When NSAIDs are necessary:
- Naproxen has the most favorable cardiovascular profile (RR 0.92-0.97) 1
- Ibuprofen shows intermediate cardiovascular risk but better GI tolerability than diclofenac at equivalent doses 6
Topical Formulation
Topical diclofenac provides equivalent efficacy to oral NSAIDs for knee and hand osteoarthritis with fewer systemic adverse events 8. This should be considered first-line for:
- Older patients
- Patients with cardiovascular risk factors
- Patients with GI, hepatic, or renal comorbidities
Topical diclofenac 2.32% gel twice daily is noninferior to 1.16% gel four times daily, offering convenient dosing 9.
Duration and Safety Window
For acute pain: Maximum 5 days for pain, 3 days for fever in OTC use 3
Cardiovascular risk considerations 10:
- Risk is dose- and duration-dependent
- Daily doses of 50-75 mg show less clear cardiovascular risk than higher doses
- Exposure <30 days shows absent or very low risk in some studies
- However, given the 2.4-fold mortality increase, even short-term use warrants caution in at-risk patients
Clinical Algorithm
Step 1: Screen for cardiovascular disease/risk factors
- If present → avoid diclofenac, use naproxen or topical NSAIDs instead
Step 2: For osteoarthritis
- Start with acetaminophen
- If inadequate → ibuprofen or topical diclofenac
- Reserve oral diclofenac for patients without CV risk factors who failed other options
Step 3: For acute pain in low-risk patients
- Diclofenac potassium 50 mg (NNT 2.1) is highly effective 5
- Use lowest effective dose for ≤5 days
- Fast-acting formulations preferred
Step 4: Discuss risks with patients before initiating treatment 7
Common Pitfalls
Prescribing to patients with cardiovascular contraindications: Studies show >10% of diclofenac initiators have cardiovascular contraindications, demonstrating widespread inappropriate use 11
Using diclofenac sodium for acute pain: This formulation has limited efficacy; use diclofenac potassium instead 5
Overlooking topical alternatives: Topical diclofenac provides equivalent pain relief with superior safety profile for appropriate indications 8
Prolonged use without reassessment: The mortality risk (RR 2.40) mandates strict adherence to shortest duration principles